APA (7th ed.) Citation

Rudd, S. G., Schaller, T., & Herold, N. (2017). SAMHD1 is a barrier to antimetabolite-based cancer therapies. Molecular & cellular oncology, 4(2), . https://doi.org/10.1080/23723556.2017.1287554

Chicago Style (17th ed.) Citation

Rudd, Sean G., Torsten Schaller, and Nikolas Herold. "SAMHD1 Is a Barrier to Antimetabolite-based Cancer Therapies." Molecular & Cellular Oncology 4, no. 2 (2017). https://doi.org/10.1080/23723556.2017.1287554.

MLA (9th ed.) Citation

Rudd, Sean G., et al. "SAMHD1 Is a Barrier to Antimetabolite-based Cancer Therapies." Molecular & Cellular Oncology, vol. 4, no. 2, 2017, https://doi.org/10.1080/23723556.2017.1287554.